A retrospective review of clinical experience with daptomycin for a variety of wound types in a burn and wound care facility.
Daptomycin is a novel antibiotic with activity against many Gram-positive organisms that has demonstrated efficacy in the management of skin and soft tissue infections (SSTIs). However, data regarding the use of daptomycin for the management of burn wound infections are lacking. We assessed the efficacy and safety of daptomycin in the treatment of complicated skin and soft tissue infections (cSSTIs), including burn wound infections. We performed a retrospective review of patients receiving daptomycin for burn wound infections and other cSSTIs in a referral burn and wound treatment center. Our review revealed an overall success rate (microbiological cure + clinically improved) of 99.5%, with an overall success rate of 98.5% among burn patients, specifically. The overall success rate was 100% among patients in the three other diagnosis groups (cSSTIs, chronic wounds, and other infections). A success rate of 98% was noted among the subset of patients with wounds associated with bacteremia. Our study suggests that daptomycin is a safe and effective agent for the management of burn wound infections, although further study is warranted to confirm these results.